Biclotymol

Biclotymol

SCHEMBL70634

Cc1c(Cl)cc(C(C)C)c(O)c1Cc1c(C)c(Cl)cc(C(C)C)c1O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 3/20 0.54
CYP2C19 P33261 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TP53 P04637 2/20 0.54
CYP2C9 P11712 1/20 0.54
GABRA1 P14867 5/20 0.48
GABRB1 P18505 4/20 0.48
LMNA P02545 5/20 0.47
SIRT1 Q96EB6 1/20 0.43
SLC6A2 P23975 3/20 0.42
HTR2B P41595 3/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CHRM1 P11229 2/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
PTGS1 P23219 2/20 0.42
HTR2C P28335 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biclotymol SCHEMBL31496050 1.00 HIF1A (0.54) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9
SCHEMBL19235936 0.93 CYP2C19 (0.49) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9
SCHEMBL29810169 0.89 GABRA1 (0.48) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9
SCHEMBL572969 0.89 GABRA1 (0.48) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9
SCHEMBL10988786 0.86 GAA (0.43) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9
SCHEMBL70212 0.82 HIF1A (0.63) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9
SCHEMBL4235931 0.82 GABRA1 (0.42) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9
SCHEMBL70105 0.81 CA1 (0.45) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9
SCHEMBL6283809 0.76 GABRA1 (0.50) HIF1AGABRA1GABRB1LMNASLC6A2
SCHEMBL4613445 0.75 GABRA1 (0.54) HIF1ACYP2C19SMN1; SMN2TP53CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
US-20200246573-A1 NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS STREETERVILLE CAPITAL, LLC 2020-08-06 US claimed
US-9499587-B2 Gamma-AApeptides with potent and broad-spectrum antimicrobial activity UNIVERSITY OF SOUTH FLORIDA (US) 2016-11-22 US claimed
US-20150274782-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY UNIVERSITY OF SOUTH FLORIDA (US) 2015-10-01 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2013112548-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY UNIVERSITY OF SOUTH FLORIDA (US) 2013-08-01 WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-4548975-A2 NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS Beyond Air Ltd (IL) 2025-05-07 EP disclosed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US disclosed
US-20250017879-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF Bio Logic Crop Science S.L. (ES) 2025-01-16 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
US-4683345-A CONDENSATION, SULFURIC ACID CATALYST Nouvel, Colette (FR) 1987-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017879-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF SARS1, ACE2, PHOSPHO1 HIF1A 2064/4885CYP2C19 1900/4885SMN1; SMN2 1062/4885
US-20150274782-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY ANPEP, DNPEP, ENPEP HIF1A 2628/4885CYP2C19 2211/4885SMN1; SMN2 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.